Xcell Therapeutics Inc. (KOSDAQ:373110)
South Korea
· Delayed Price · Currency is KRW
1,773.00
-24.00 (-1.34%)
Apr 29, 2026, 3:30 PM KST
Xcell Therapeutics Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 30,663 | 28,726 | 44,384 | - | - | - | |
| Market Cap Growth | -18.98% | -35.28% | - | - | - | - | |
| Enterprise Value | 29,244 | 33,873 | 38,298 | - | - | - | |
| Last Close Price | 1773.00 | 1661.00 | 3373.54 | - | - | - | |
| PS Ratio | 15.73 | 14.74 | 22.95 | - | - | - | |
| PB Ratio | 4.30 | 4.02 | 4.87 | - | - | - | |
| P/TBV Ratio | 4.76 | 4.46 | 5.17 | - | - | - | |
| EV/Sales Ratio | 15.00 | 17.38 | 19.80 | - | - | - | |
| Debt / Equity Ratio | 0.77 | 0.77 | 0.63 | 2.73 | 0.69 | 0.38 | |
| Net Debt / Equity Ratio | -0.20 | -0.20 | -0.34 | 2.16 | 0.03 | -0.52 | |
| Net Debt / EBITDA Ratio | 0.16 | 0.16 | 0.40 | -0.70 | -0.04 | 1.80 | |
| Net Debt / FCF Ratio | 0.14 | 0.14 | 0.42 | -0.73 | -0.03 | 1.42 | |
| Asset Turnover | 0.12 | 0.12 | 0.14 | 0.09 | 0.05 | 0.10 | |
| Inventory Turnover | 3.87 | 3.87 | 4.44 | 4.01 | 4.67 | 3.87 | |
| Quick Ratio | 1.36 | 1.36 | 1.90 | 0.36 | 1.19 | 2.83 | |
| Current Ratio | 1.81 | 1.81 | 2.14 | 0.52 | 1.39 | 2.93 | |
| Return on Equity (ROE) | -134.41% | -134.41% | -165.90% | -170.80% | -67.53% | -102.65% | |
| Return on Assets (ROA) | -41.59% | -41.59% | -42.63% | -43.01% | -26.46% | -18.88% | |
| Return on Capital Employed (ROCE) | -104.40% | -104.40% | -77.90% | -177.90% | -80.40% | -30.90% | |
| Earnings Yield | -35.64% | -38.04% | -21.50% | - | - | - | |
| FCF Yield | -33.82% | -36.09% | -16.63% | - | - | - | |
| Buyback Yield / Dilution | -16.46% | -16.46% | -13.11% | -1.02% | -5.71% | -364.87% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.